Read More

Research commenced with Keio University to discover drugs using “Chemicals Informatics”

TOKYO, Jan 12, 2023 - (JCN Newswire via SEAPRWire.com) - Hitachi High-Tech Solutions Corporation, in collaboration with Keio University Faculty of Pharmacy, Department of Pharmaceutical Sciences is commencing joint research that uses Materials Informatics (MI) (the Research) to improve the efficiency of the development of small molecule drugs(1).Hitachi High-Tech Solutions will be using the "Chemicals Informatics (CI)" MI tool not only by developing materials in the traditional chemical materials field but also in the field of drug discovery, to improve quality of care and QoL (Quality of Life) for people.Background to the ResearchSmall molecule drugs are mainstream drugs in the modern world, and in recent years, expectations for their use have increased, with the development of drugs such as molecular-targeted drugs that inhibit the action of proteins, which cause cancer(2). Traditionally, the process used to develop small molecule drugs has involved researchers using their knowledge and experience to select several potential compounds from an extensive library of existing compounds and then repeating experiments to adjust the structure of a compound and clarify the mechanism by w...

Read More

Elevating Australia’s Scientific Acumen: Large Molecule Facility Doubles Size of Australia’s Top Bioanalytical Laboratory

Thebarton, Australia, May 12, 2022 – (NovationWire) – Agilex Biolabs Pty Ltd has unveiled its new building with a ribbon cutting ceremony by The Honourable Stephen Patterson MP Minister for Trade and Investment at 12:30pm on Thursday 17 February 2022 at 31 Dalgleish street Thebarton South Australia 5031. Agilex Biolabs launched its new laboratory for the analysis of large molecule therapeutics, more than doubling the geographic area of its Adelaide campus. The addition of this 2,520 m2 facility expands the service capabilities of Australia’s most technologically advanced bioanalytical partner and brings a new point of pride to South Australia. State-of-the-art instrument platforms and increased capacity empower drug sponsors from all over the world to succeed as they expand into the novel, promising world of large molecule therapeutics. Areas of medicine such as oncology are seeing new ways of approaching treatment due to innovative modalities like antibody-drug conjugates (ADCs) and allogeneic cell therapies. Gene therapies and vaccines created using genetic platforms such as RNA, miRNA, and siRNA need specialised tools and technology to measure critical safety and efficacy endpoi...